Arranta Bio Doubles RNA Process Development Capacity at Massachusetts Plant
Project addresses customer demand in GMP-powered advanced therapeutics.
Arranta Bio, a contract development and manufacturing organization (CDMO) in the advanced therapy space, has doubled capacity at its Watertown, Mass. facility for process development services supporting RNA therapeutics. This comes less than a year after the CDMO was acquired by Recipharm. The expansion involves the fit out of an approximately 2,000 square-foot lab space that includes modular small scale and pilot scale equipment, which is able to provide development and scale up to good manufacturing practice (GMP) manufacturing.
The 80,000 square-foot Watertown site features Grade C production suites intended for the production of mRNA, lipid nanoparticle formulation, and automated sterile fill-finish into vials or syringes within a gloveless, robotic isolator. The facility has capabilities for process and analytical development, along with GMP manufacturing for drug substance and drug product.
“The opening of our additional development laboratory space for RNA technologies at Watertown means we are well positioned to help our clients quickly and effectively scale up processes for successful GMP manufacturing,” says David Stevens, Arranta Bio’s CEO.
Touchlight, University of Nottingham Collaborate on Development of Zika Vaccine
August 21st 2024Although it still has to undergo the preclinical and clinical trial process, the DNA vaccine—which could be created in as little as six weeks—does not require the cold chain storage that mRNA jabs often demand.
